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Abstract
Background:
There is ample evidence to support the efficacy of sublingual immunotherapy (SLIT) on allergic rhinitis, while
there is less solid data regarding asthma. We evaluated the effects of a high dose birch SLIT on birch-
induced rhinitis and asthma in a controlled study.
Methods:
This double-blind, placebo-controlled, randomised, single centre trial on SLIT with birch pollen allergen
extract (Stallergenes, Antony, France) included 24 patients presenting severe rhinitis and slight to moderate
asthma, 14 actively and 10 placebo treated. SLIT was performed by a pre-coseasonal protocol, and was
repeated for 2 years. The study plan included a selection visit, a visit at the start of the first and the second
treatment cycle, a follow-up visit after 1–3 months from the start of each cycle, and a final visit at the end of
each yearly cycle.
Results:
A significant decrease (p50.05) in rhinorrhoea and nasal obstruction occurred in actively treated patients.
The median number of days with asthma at visit 3 was 10 (0–27) in the active (SLIT) group and 13 (0–29) in
the placebo group. The median number of days with asthma at visit 6 was 2 (0–6) in the SLIT group and 7
(0–15) in the pl cebo group (p50.05 between groups). A stepdown of asthma occurred in 77% of actively
treated vs. none of placebo treated patients (p¼ 0.05). No severe adverse events were observed.
Conclusions:
This pilot study suggests that SLIT with high dose birch extract may be able to step down seasonal
pollen-induced asthma after prolonged treatment.
Introduction
Sublingual immunotherapy (SLIT) was introduced with the aim of improving
the safety of allergen immunotherapy, which in its traditional, subcutaneous
injection route faced the problem of systemic reactions1. A number of
meta-analyses on SLIT are available, demonstrating sound evidence of efficacy
regarding allergic rhinitis2,3, while contrasting data were obtained in allergic
asthma. In fact, a meta-analysis in children and adolescents detected a good
efficacy4, while in a global meta-analysis the difference between actively and
placebo treated patients was less significant5.
Generally, randomised controlled trials on SLIT in allergic asthma have as
their primary objective symptom and medication scores, while the severity
assessment of asthma suggested in the Global INitiative on Asthma (GINA)
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international guidelines6, based on the frequency of asth-
matic symptoms, is not used as a parameter to measure the
clinical efficacy of the treatment. In the present double-
blind, placebo-controlled, randomised, pilot study, we
evaluated the effects of SLIT on birch-induced rhinitis
and asthma, using for the latter the standards by GINA
and EPR-37.
Methods
The trial was conducted in the Allergy Unit of the
San Martino Hospital in Genoa, Italy, and included 24
patients, 14 actively (7 males, 7 females, mean age
43.8 9.4 years) and 10 (3 males, 7 females, mean age
39.9 6.6 years) placebo treated. All patients were mono-
sensitised to Betulaceae pollen and had moderate/severe
persistent rhinitis according to ARIA criteria8 and slight
intermittent to moderate persistent asthma (level I to III)
according to GINA criteria6 during the previous birch
pollen season, as evaluated by diary cards registered from
February to April. SLIT was performed using an allergen
extract of birch at 10 Index of Reactivity (IR)/ml and 300
IR/ml (Stallergenes, Antony, France), with a build-up
phase over 11 days started with 10 IR and culminating at
300 IR. It was then used in the maintenance phase by daily
administration for 4 months. Patients were divided into
active or placebo treatment groups using a computer-
generated randomisation list. Placebo vials matched the
active treatment in colour and flavour in order to ensure
the double-blindness but contained no pollen allergens or
other active ingredients. Active or placebo doses were
taken sublingually in the morning before breakfast. The
SLIT treatment was repeated over 2 consecutive years.
The study plan included 6 visits, at selection (visit 1), at
the start of treatment (visit 2), during the pollen season
(visit 3), at the start of second year of treatment (visit 4),
during maintenance treatment (visit 5), and at the end of
treatment during the pollen season (visit 6). For the full
duration of the trial patients recorded on diary cards the
occurrence of symptoms (graded by a scale from 0¼ no
symptoms to 3¼ very bothering symptoms) of rhinitis
(sneezing, rhinorrhoea, nasal obstruction) and asthma
(dyspnoea, chest constriction, wheezing). Days in which
a 0 score was registered for lung symptoms were considered
days without asthma. The consumption of drugs, including
antihistamines (loratadine, desloratadine, cetirizine),
topical nasal (fluticasone propionate) and bronchial (flu-
ticasone propionate) corticosteroids, and inhaled bronch-
odilators (formoterol), used as needed, was registered on
the same diary cards. Concerning asthma, the drug use
defined the treatment step according to GINA criteria,
that is, using only the bronchodilator defined step 1,
using low dose bronchial corticosteroid defined step 2,
using low dose bronchial corticosteroid plus the
bronchodilator defined step 3, and using high dose
bronchial corticosteroid plus the bronchodilator defined
step 46.
The primary objective of the study was to assess the
immunological reactivity by dosing birch-specific IgE
and IgG, ECP and tryptase at the nasal mucosa level.
This is analysed in another article (manuscript in prepara-
tion). The secondary objectives were to assess the rhinitis
and asthma symptoms and the safety of SLIT. The trial was
approved by the San Martino Hospital ethical committee
and was performed in accordance with the declaration
of Helsinki and Good Clinical Practice. All patients
gave a written informed consent before entering the study.
Statistical method
Due to the small number of patients included in the pilot
study, nonparametric tests were used. This choice of a
nonparametric method gave us the possibility of a statisti-
cal analysis with fewer assumptions, as our data had a rank-
ing but not completely clear numerical interpretation
(part of the symptoms not objective).
The Mann–Whitney U test was used to compare the
scores registered at the different visits, the univariate ana-
lysis was used to compare the number of days with asthma.
The results were expressed as median values with 5–95
percentiles. The chi squared test was used to compare
the number of subjects showing a stepdown of asthma in
the two groups. A p value50.05 was set as significant.
Results
There were two dropouts during the study, one actively
and one placebo treated. Table 1 shows the characteristics
of patients completing the study. The mean cumulative
dose administered in each pre-coseasonal course was
13.800 IR, corresponding to 6.900mcg of the major
birch allergen Bet v 1. The efficacy of SLIT on rhinitis
was demonstrated by a significant decrease (p50.05) in
rhinorrhoea and nasal obstruction in actively treated
patients during the pollen season at the first year of treat-
ment (Table 2). The median number of days with asthma
at visit 3 was 10 (0–27) in the actively treated group and
Table 1. Characteristics of patients at inclusion.
Active group
(13 pts)
Placebo group
(9 pts)
Gender 7 males 6 males
Mean age (years) 43.8 39.3
Asthma level 1 4 2
Asthma level 2 5 5
Asthma level 3 4 2
Mean FEV1 value (% predicted) 100.9% 101.2%
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13 (0–29) in the placebo group (nonsignificant differ-
ence), while the results were 2 (0–6) in the actively treated
group and 7 (0–15) in the placebo group at visit 6 during
the pollen season of the second year (p50.05). This is
shown in Figure 1. The asthma severity assessed by
GINA criteria stepped down in 10 of 13 actively treated
patients compared with 0 of 9 placebo treated patients
(p¼ 0.05). As regards safety and tolerability, at least one
adverse event (AE) was reported by 75% of actively trea-
ted and 44.4% of placebo treated patients, most AEs being
slight/moderate and consisting of local reaction in the
mouth. There was no need to stop treatment in this case.
Discussion
The efficacy of subcutaneous immunotherapy (SCIT) in
allergic asthma is established by a sound meta-analysis of
75 double-blind, placebo-controlled studies9. SLIT has
demonstrated a substantial therapeutic equivalence to
SCIT in allergic rhinitis, provided that high doses – i.e.
corresponding to at least 50–100 times the doses adminis-
tered with SCIT8 – are used. This noninferiority to SCIT
has also been demonstrated by a direct comparison
between the two methods of immunotherapy in patients
with birch allergic rhinitis10,11. However, the effectiveness
of SLIT in asthma remains object to discussion, with good
evidence of efficacy being obtained in paediatric popula-
tions4 but not in adults5. The present study confirms once
again that SLIT with high dose birch extract is able to
significantly reduce the nasal symptoms to the specific
allergen during the first year of treatment, including
nasal obstruction, which is the most critical symptom
and is related to the infiltration of inflammatory cells
and their products in the nose. However, the object of
the study was to investigate whether SLIT would be able
to induce a stepdown of allergic asthma as assessed by
GINA criteria. In the first season of treatment, the
median number of days with asthma registered by actively
treated patients was nonsignificantly lower compared with
the placebo treated group. In the second year of treatment,
the median number of days with asthma in the actively
treated group was significantly lower than in placebo trea-
ted group (2 vs. 7 days) and reached statistical significance
also regarding the number of patients showing a stepdown
of the GINA level of asthma severity. These findings sug-
gest that SLIT may be able to induce a stepdown of sea-
sonal asthma. However, in order to arrive at this outcome
requires more time compared with the clinical control of
allergic rhinitis.
The present study has its main limitation in the low
number of patients. The sample size calculation would
have required 14 patients in each group, but due to the
difficulty of finding monosensitised adult patients this
number was not reached. Also, the possible non-normal
distribution of data due to small sample size dictated the
choice of using nonparametric tests, which gave us the
possibility of a statistical analysis with fewer assumptions.
This is why the trial must be considered a pilot study, and
controlled trials on larger populations are required to con-
firm its findings and observations. Considering that most
SLIT studies included in meta-analysis2–5 are single year
trials, future investigations on SLIT in asthma would need
to be based on a longer (at least two-year) time period.
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Table 2. Symptom scores (median with 5–95 percentiles in actively and placebo treated patients).
Symptom score (median
with 5–95 percentiles)
Active group Placebo group
Rhinorrhoea Before SLIT
2 (1–3)
After 1 yr SLIT
1 (0–2)
Before SLIT
2 (1–3)
After 1 yr SLIT
1.5 (0–2)
Nasal obstruction Before SLIT
2 (1–3)
After 1 yr SLIT
1.5 (0–2)
Before SLIT
2 (2–3)
After 1 yr SLIT
2 (0–3)
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Figure 1. Number of days with asthma (median) at the first (visit 3) and the
second (visit 6) year of treatment in 13 actively and 9 placebo treated
patients.
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